PDL/Roche Targeting Broad Zenapax Asthma Indication Under Development Deal

Roche signs on to PDL’s plans for daclizumab in development/marketing agreement for “asthma and related respiratory diseases.” PDL hopes initial asthma indication will be broader than that of Genentech/Novartis’ Xolair.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet